Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelios Towers Regulatory News (HTWS)

Share Price Information for Helios Towers (HTWS)

Share Price is delayed by 15 minutes
Get Live Data
223.60    1.00 (0.45%)
Bid:
223.40
Ask:
223.60
Spread: 0.20 (0.09%)
Market Cap: £2.29b
HTWS Live PriceLast checked at - London Stock Exchange

Intraday Helios Towers Share Chart

Tender Results Announcement

31 May 2024 16:35

RNS Number : 7102Q
Helios Towers PLC
31 May 2024
Β 

NOT FOR DISTRIBUTION IN OR INTO ANY JURISDICTION OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION IN WHICH SUCH DISTRIBUTION IS UNLAWFUL

HELIOS TOWERS ANNOUNCES RESULTS OF ITS OFFER TO PURCHASE FOR CASH ANY AND ALL OF THE OUTSTANDING 7.000% SENIOR NOTES DUE 2025

May 31, 2024 - HTA Group, Ltd. (the "Offeror"), a wholly owned subsidiary of Helios Towers plc (the "Company"), announces the results to date of its previously announced offer to purchase for cash (the "Tender Offer") the 7.000% Senior Notes due 2025 issued by the Offeror (the "Notes"). The Tender Offer is made upon the terms and subject to the conditions set forth in the offer to purchase dated May 20, 2024 (the "Offer to Purchase").

Capitalized terms in this announcement and not defined have the meaning assigned to them in the Offer to Purchase dated May 20, 2024, which is available, subject to eligibility and registration, on the tender offer website (the "Tender Offer Website"): https://projects.morrowsodali.com/HTA.

As of 5:00 p.m., New York City time, on May 30, 2024 (the "Expiration Time"), U.S.$549,214,000 aggregate principal amount of the Notes were validly tendered and not validly withdrawn pursuant to the Tender Offer (equal to approximately 84.5% of the principal amount of Notes outstanding). The following table identifies the Purchase Price, the principal amount of Notes validly tendered and not validly withdrawn and the principal amount of Notes the Offeror has accepted for purchase, as well as the outstanding principal amount:

Description of the Notes

ISIN/CUSIPs

Purchase Price

Principal Amount Tendered(1)

Outstanding Principal Amount Following Settlement of the Tender Offer

7.000% Senior Notes due 2025

Regulation S:

XS2189784957

Rule 144A:

US40435WAB63 / 40435WAB6

U.S.$1,000 per U.S.$1,000 in principal amount of the Notes

U.S.$549,214,000

U.S.$100,808,000

(1) No Notes were tendered under the Guaranteed Delivery Procedures.

In addition to the Purchase Price, Holders whose Notes are accepted for purchase will be paid an Accrued Interest Amount. Accrued Interest will cease to accrue on the Settlement Date.

The Purchase Price and the Accrued Interest for the Notes validly tendered (and not validly withdrawn) in the Tender Offer will be paid on the Settlement Date subject to any postponement of the Settlement Date as described in the Offer to Purchase. The Settlement Date for the Tender Offer will be June 4, 2024.

The Tender Offer has now expired, and no further Notes can be tendered for purchase. All Notes accepted for purchase pursuant to the Tender Offer will be cancelled.

On May 20, 2024, the Company issued a notice of redemption for all of the Notes that remain outstanding following the completion of the Tender Offer, with June 18, 2024 being the date fixed for such redemption.

On May 22, 2024, the Offeror completed the successful pricing of an offering of new notes (the "New Notes Offering") guaranteed by the Company and certain of its direct and indirect subsidiaries. A portion of the proceeds from the New Notes Offering is expected to fund the Tender Offer. The Offeror expects the settlement of the New Notes Offering to occur on June 4, 2024. The settlement of the New Notes Offering will satisfy the Financing Condition (as defined in the Offer to Purchase).

The Offeror has retained Merrill Lynch International, J.P. Morgan Securities plc, The Standard Bank of South Africa Limited and Standard Chartered Bank to act as the Dealer Managers for the Tender Offer and Morrow Sodali Limited to act as Information and Tender Agent for the Tender Offer. Questions regarding procedures for tendering Notes may be directed to Morrow Sodali Limited at +852 2319 4130 (Hong Kong), +44 20 4513 6933 (Europe), +1 203 609 4910 (U.S.) or by email to HTA@investor.morrowsodali.com. Questions regarding the Tender Offer may be directed to J.P. Morgan Securities plc by email to em_europe_lm@jpmorgan.com; Merrill Lynch International at +44 20 7996 5420 (Europe) or +1 (888) 292-0070 (U.S. Toll Free) or by email to DG.LM-EMEA@bofa.com; the Standard Bank of South Africa Limited by email to LiabilityManagement@standardsbg.com or Standard Chartered Bank at +44 20 7885 5739 (Europe) or +1 212 667-0351 (U.S.) or by email to liability_management@sc.com.

This announcement is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security. No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offer is only being made pursuant to the Offer to Purchase. Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the Tender Offer. Any notes issued pursuant to the New Notes Offering and the guarantees in respect thereof have not been and will not be registered under the United States Securities Act of 1933. Neither the Tender Offer nor this announcement is an offer to sell or a solicitation of an offer to buy any notes issued pursuant to the New Notes Offering. No action has been or will be taken in any jurisdiction in relation to any notes issued pursuant to the New Notes Offering to permit a public offering of securities.

The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required by each of the Offeror, the dealer managers and the information and tender agent to inform themselves about and to observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Forward-Looking Information

Certain statements included herein may constitute forward-looking statements within the meaning of the securities laws of certain jurisdictions. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "are expected to", "intends", "will", "will continue", "should", "would be", "seeks", "anticipates" or similar expressions or the negative thereof or other variations thereof or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Offeror concerning, among other things, the results in relation to operations, financial condition, liquidity, prospects, growth and strategies of the Offeror and the industry in which it operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

These forward-looking statements speak only as of the date of this announcement. The Offeror does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under Rule 14e-1 under the United States Securities Exchange Act of 1934.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCFLFLSEVILVIS
Date   Source Headline
8th Jun 20267:00 amRNSTransaction in Own Shares
5th Jun 20263:41 pmRNSHolding(s) in Company
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20263:26 pmRNSTotal Voting Rights
28th May 202610:15 amRNSHolding(s) in Company
26th May 20267:00 amRNSTransaction in Own Shares
20th May 202612:13 pmRNSHolding(s) in Company
20th May 20267:00 amRNSHolding(s) in Company
18th May 20267:00 amRNSTransaction in Own Shares
15th May 20261:10 pmRNSDirector/PDMR Shareholding
14th May 20261:12 pmRNS2026 Annual General Meeting Results
11th May 20267:37 amRNSTransaction in Own Shares
8th May 20267:11 amRNSHolding(s) in Company
7th May 20267:00 amRNSQ1 2026 Results
5th May 20267:00 amRNSTransaction in Own Shares
1st May 20268:47 amRNSHolding(s) in Company
30th Apr 20264:03 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 202612:20 pmRNSHolding(s) in Company
8th Apr 202610:49 amRNSNotice of Q1 2026 Results Date & Conference Call
7th Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20262:34 pmRNSTotal Voting Rights
30th Mar 20269:50 amRNSAnnual Report and Notice of AGM
30th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 202612:00 pmRNSDirector/PDMR Shareholding
25th Mar 20266:08 pmRNSHelios Towers announces pricing of Senior Notes
24th Mar 202611:43 amRNSLAUNCH OF OFFER OF SENIOR NOTES
23rd Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20263:14 pmRNSDirector/PDMR Shareholding
16th Mar 20263:14 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSFull Year Results 2025
12th Mar 20267:00 amRNSFull Year Results 2025
9th Mar 20264:15 pmRNSDirectorate change
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20264:19 pmRNSTotal Voting Rights
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.